[Hiring] Medical Science Liaison @Revolution Medicines

Role Description

We are seeking a highly motivated and experienced professional to join our team as a Medical Science Liaison, Netherlands. Key aspects of this role will include:

• Engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights.
• Serve as a therapeutic expert and thought partner to internal teams.
• Liaison between Revolution Medicines and clinical study sites / investigators.
• Provide support for medical education, advisory boards, and medical congresses.

Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for:

• Cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in various phases of product development.
• Collaborating with stakeholders within medical affairs and across the organization, including but not limited to Clinical Development, Commercial, Program Management, Clinical Operations, and Compliance teams.

The ideal candidate is an effective communicator, driven, detail-oriented, proactive, and a skilled collaborator.

Qualifications

• Doctoral degree in scientific or medical discipline.
• 8+ years experience as an MSL or in a similar role within the pharmaceutical or biotech industry in Netherlands.
• Strong understanding of clinical research methodologies and drug development processes.
• Knowledge and experience within the oncology therapeutic area, preferred experience in lung and gastrointestinal cancers.
• Excellent verbal and written communication skills.
• Proven ability to analyze and synthesize scientific information effectively.
• Excellent presentation skills, with the ability to effectively communicate complex scientific data to diverse audiences.
• Strong networking skills with proven ability to successfully build and maintain relationships with KOLs and healthcare professionals.
• Self-directed and able to thrive in a fast-paced and dynamic environment.
• Willingness to travel up to 60% of time.

Requirements

• Develop and maintain strong relationships with KOLs, healthcare professionals, and academic institutions to advance scientific and medical knowledge.
• Communicate clinical and scientific data to KOLs and healthcare professionals through presentations, educational programs, and scientific discussions.
• Support the synthesis and communicate scientific insights from KOLs to relevant internal teams.
• Provide scientific support for medical congresses, advisory boards and other relevant scientific engagements to enhance the visibility of RevMed within the scientific and medical communities.
• Establish credibility as a scientific expert and resource for internal stakeholders, providing medical and scientific support for products and therapeutic areas.
• Collaborate cross-functionally with medical affairs, clinical development, marketing and other teams to support the development and execution of medical strategies and tactics.
• Stay current with scientific literature, emerging research, and competitive landscape.
• Adhere to Revolution Medicines Core Values and policies.
• Understand the regulatory requirements for customer engagement by field-based employees.

Company Description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), elironrasib (RMC-6291), zoldonrasib (RMC-9805), and RMC-5127 are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.